ResearcherShanxi Medical UniversityActive in the last 2 years

Peng Yao

ORCID-verified (high confidence)As of 15 November 2026

Matched on ORCID iD 0009-0003-7292-5889.

Their work

Counts cover pancreatic cancer work only: a researcher’s other papers, trials and grants are not in these records.

Pancreatic cancer papers: 1 (first author 0, last author 1)
Pancreatic cancer trials: 0
Pancreatic cancer grants: 0
Collaborators: 1

Papers, trials and grants by year

2026: 1 paper

Papers 1

RE: Benefit of adjuvant chemotherapy for resected pancreatic cancer following neoadjuvant FOLFIRINOX or Gemcitabine-Nab-paclitaxel: a multinational analysis. Last author DOI 10.1093/jnci/djag312 ↗

Closest collaborators

The 1 strongest of 1 ranked by shared papers, trials and grants, with recent and small-team work weighing most.

Jiayong Ning · 1 shared paper, 2026
- Paper RE: Benefit of adjuvant chemotherapy for resected pancreatic cancer following neoadjuvant FOLFIRINOX or Gemcitabine-Nab… DOI 10.1093/jnci/djag312 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (the fewest links first, then the links with the most shared work). Built from public records only; no contact details are kept.